BetterLife Pharma Inc.

What they do

BetterLife Pharma is an emerging biotechnology company primarily focused on developing compounds for the treatment of mental disorders. It is also refining and developing drug candidates from a broad set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company was incorporated in British Columbia on June 10, 2002, and changed its name from Pivot Pharmaceuticals Inc. to BetterLife Pharma Inc. on December 5, 2019. Its common shares trade on the Canadian Securities Exchange under the symbol BETR.

Revenue drivers

• Mental disorder compounds — Primary focus is developing compounds for treatment of mental disorders, but no revenue has been generated from this pipeline to date.
• Interferon-based antiviral technologies — The company is refining and developing drug candidates from complementary interferon-based technologies, but no revenue has been recognized from these efforts.

Recent performance

For the fiscal year ended January 31, 2026, BetterLife reported no revenue, an operating expense of $1,607,739, other income of $94,821, and a net loss of $1,512,918. The net loss per share was $0.01, based on a weighted average of 145,880,325 shares outstanding. As of January 31, 2026, cash was $12,570, compared to $8,180 at January 31, 2025, and $37,384 at January 31, 2024. The company had an accumulated deficit of $120,091,493 as at January 31, 2026.

Strategy

Management intends to continue to pursue additional financing through issuances of equity or debentures. The company's continued operations are dependent on its ability to generate future cash flows through additional financing or commercialization. There is no assurance that additional funding will be available on a timely basis or on terms acceptable to the company. No specific development milestones or partnership plans are disclosed in the provided excerpts.

Risks

• Going concern — The company has not earned any revenue and has an accumulated deficit of $120,091,493, indicating a material uncertainty that casts substantial doubt on its ability to continue as a going concern.
• Financing risk — Continued operations depend on additional financing, and there is no assurance that funding will be available on a timely basis or on acceptable terms.
• No revenue history — The company has never generated revenue, with net losses reported in recent fiscal years, including a net loss of $1,512,918 for fiscal 2026.
• Dilution risk — Management plans to pursue additional financing through issuances of equity or debentures, which could dilute existing shareholders.

Outlook

Management states that continued operations are dependent on generating future cash flows through additional financing or commercialization. The company intends to pursue additional financing through equity or debenture issuances, but there is no assurance that such funding will be available on a timely basis or on acceptable terms. These conditions indicate a material uncertainty that casts substantial doubt on the company's ability to continue as a going concern. No specific timelines or milestones for product development or commercialization are provided.